SUPPRELIN Drug Patent Profile
✉ Email this page to a colleague
When do Supprelin patents expire, and what generic alternatives are available?
Supprelin is a drug marketed by Shire and Endo Operations and is included in two NDAs. There is one patent protecting this drug.
The generic ingredient in SUPPRELIN is histrelin acetate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the histrelin acetate profile page.
DrugPatentWatch® Generic Entry Outlook for Supprelin
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SUPPRELIN?
- What are the global sales for SUPPRELIN?
- What is Average Wholesale Price for SUPPRELIN?
Summary for SUPPRELIN
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 11 |
| Clinical Trials: | 2 |
| Patent Applications: | 750 |
| Drug Prices: | Drug price information for SUPPRELIN |
| What excipients (inactive ingredients) are in SUPPRELIN? | SUPPRELIN excipients list |
| DailyMed Link: | SUPPRELIN at DailyMed |
Recent Clinical Trials for SUPPRELIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Southwest Oncology Group | Phase 3 |
| National Cancer Institute (NCI) | Phase 3 |
| University of Colorado, Denver | Phase 2 |
US Patents and Regulatory Information for SUPPRELIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shire | SUPPRELIN | histrelin acetate | INJECTABLE;INJECTION | 019836-001 | Dec 24, 1991 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Endo Operations | SUPPRELIN LA | histrelin acetate | IMPLANT;SUBCUTANEOUS | 022058-001 | May 3, 2007 | RX | Yes | Yes | 8,062,652 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shire | SUPPRELIN | histrelin acetate | INJECTABLE;INJECTION | 019836-002 | Dec 24, 1991 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shire | SUPPRELIN | histrelin acetate | INJECTABLE;INJECTION | 019836-003 | Dec 24, 1991 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SUPPRELIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Shire | SUPPRELIN | histrelin acetate | INJECTABLE;INJECTION | 019836-001 | Dec 24, 1991 | 4,244,946 | ⤷ Start Trial |
| Shire | SUPPRELIN | histrelin acetate | INJECTABLE;INJECTION | 019836-003 | Dec 24, 1991 | 4,244,946 | ⤷ Start Trial |
| Shire | SUPPRELIN | histrelin acetate | INJECTABLE;INJECTION | 019836-002 | Dec 24, 1991 | 4,244,946 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SUPPRELIN
See the table below for patents covering SUPPRELIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 2617 | ⤷ Start Trial | |
| Australia | 533348 | ⤷ Start Trial | |
| Australia | 5866380 | ⤷ Start Trial | |
| Canada | 1154758 | PEPTIDES HYDROSOLUBLES AYANT UNE ACTION SUR LES GONADES (WATER-SOLUBLE PEPTIDES AFFECTING GONADAL FUNCTION) | ⤷ Start Trial |
| Germany | 3062118 | ⤷ Start Trial | |
| Denmark | 149896 | ⤷ Start Trial | |
| Denmark | 241780 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch